Open Accessibility Menu

Cancer Annual Report

Washington DC Cancer Statistics

Our Cancer Annual Report provides an overview of the cancer registry data for patients treated at GW Hospital and The GW Medical Faculty Associates in the previous year, detailing trends in cancer care at GW in comparison to national American Cancer Society data.

The report also highlights many of the achievements of the GW Cancer Center's cancer initiatives - focused on community outreach, clinical care, research, and survivorship. In addition, the report lists contact information for GW's many cancer patient resources.

2014 GW Cancer Annual Report

We are pleased to present the 2014 Academic Comprehensive Cancer Program and the Comprehensive Breast Care Program Report for GW’s School of Medicine and Health Sciences (SMHS), GW Hospital, and The GW Medical Faculty Associates (GW MFA). In it, you will find information about our efforts in clinical care, community, research, and survivorship.

Download the PDF

2012 GW Cancer Annual Report

We are pleased to present the 2012 Annual Report of the Cancer Program for the George Washington University. We are proud to have been recognized by the Commission on Cancer for creating a model program for optimal cancer survivorship. In the coming year we will build on our accomplishments as we continue to develop and improve our program.

Download the PDF

Conveniently Located
  • September - 2019
  • October - 2019
    • 28 - Monday

      All events are appointment only, and first come first serve. Patients must pre-register with the site/company listed and we do allow walk-ins as long as we can confirm that the patient has a referring ...

      More Information
    • 12 - Saturday
      Free Prostate Screening -
      10:00am - 2:00pm

      Join the GW Cancer Center and Giant for free prostate and colorectal screenings on Saturday, October 12 from 10 a.m. - 2 p.m. Get screened and learn about hereditary prostate cancer and dietary ...

      More Information
Related Blog Articles
  • Help Save Lives By Supporting The GW Mammovan

    According to the Centers for Disease Control, women in the Washington, D.C. area have higher breast cancer mortality rates and one of the highest breast cancer incidence rates in the nation . ...

    Read Full Article

Clinical Trials

  • Comparing Group Approaches to Improve Insomnia Symptoms Among Breast Cancer Survivors
    We are inviting women diagnosed with stage I-III breast cancer who have completed active treatment (e.g. surgery, chemotherapy, radiation) to participate in this research study. Through this study we will examine if our mind and body programs improve some of the long term effects of breast cancer treatment such as insomnia. This is a pilot phase of the study. This means that we are interested in feasibility of the program and will ask for your feedback about things you like and do not like about the program.
  • Combination immunotherapy with Herceptin and theHER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
    This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+
  • A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative early Breast Cancer (PALLAS Study)
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
    This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
  • A Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for The Treatment of men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study
    The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.